Social Anxiety Breakthrough or Overhyped Experiment? AtaiBeckley's R-MDMA Divides Opinion
AtaiBeckley (ATAI) tested an R-MDMA pill for social anxiety. Results looked promising — but the trial was tiny, just 6 weeks, and far from FDA approval.
/ 898 items
#Healthcare↓
Eikon Therapeutics Hit with Underperform Call – TLR7/8 Struggles and Crowded PARP Field Cited
Wedbush starts coverage on Eikon Therapeutics with an Underperform rating and $7 price target, citing high risks in its cancer drug pipeline including a struggling TLR7/8 agonist and crowded PARP1 inhibitors.
CRISPR Therapeutics Jumps on Takeover Buzz
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
Novavax Hits Profit in Q4 2025 & Raises 2026 Revenue Forecast
Novavax reports strong 2025 results, first Q4 profit in years, and boosts 2026 outlook thanks to Pfizer & Sanofi deals.
Wall Street Bears Circle Sarepta: Sell Ratings Pile Up After Q4 Reset Warnings
Major analysts like Citi, Needham, and Bank of America maintain Sell ratings on Sarepta after recent updates, citing risks to key products like Elevidys, lower 2026 outlook, and regulatory concerns in Duchenne muscular dystrophy treatments.
PROCEPT BioRobotics Hit With Downgrade After Q4 Miss and Strategy Shift
Bank of America just cut PRCT’s rating to Underperform and slashed its price target from $38 to $20 after a weak Q4 miss.